Patients prefer new diabetes drug Victoza over its competitor, survey finds
MONTREAL A new diabetes drug satisfied patients more than its competitor, according to a study funded by the drug’s manufacturer.
According to data on 379 patients who took the Diabetes Treatment Satisfaction Questionnaires, presented Thursday at the 20th World Diabetes Congress and published in medical journal The Lancet, patients taking Novo Nordisk’s drug Victoza (liraglutide) perceived less abnormally low or high blood sugar levels — known respectively as hypoglycemia and hyperglycemia — than those taking Byetta (exenatide), made by Eli Lilly & Co., Amylin Corp. and Alkermes.
Victoza is approved in Europe, but Novo Nordisk is still waiting for approval from the Food and Drug Administration in the United States.
“Liraglutide has shown here in a convincing study that it is associated with less nausea, less perceived hypoglycemia and definitely higher patient satisfaction compared to exenatide,” principal investigator Wolfgang Schmidt said in a statement. “Patient-reported outcomes data is an important extension of the efficacy data. If a patient is satisfied with his or her treatment, then they are much more likely to really stick to the treatment over the long term, which is necessary in Type 2 diabetes.”
Schnuck exec honored by produce pub
ST. LOUIS A weekly newspaper serving the produce industry has given a top award to a Schnuck Markets executive.
The Packer named Schnucks VP produce and floral Michael O’Brien the 2009 “Marketer of the Year,” Schnucks announced, presenting him with the award at the Produce Marketing Association’s Fresh Summit earlier this month.
O’Brien has worked in the supermarket industry for 37 years, starting at Schnucks as a bagger in 1972, becoming a store manager in 1983 and division manager in 1990. He has served in his current position since 2001.
Schnucks said O’Brien had taken an “active role” in promoting produce consumption and was a member of a number of industry organizations. He is chairman-elect of the PMA’s board of directors and served as chairman of the Produce for Better Health Foundation in 2007, promoting that organizations “5 a day, Fruits & Veggies – More Matters” campaign to promote the eating of fruits and vegetables. Produce Merchandising magazine also named him “Retailer of the Year” in 2004.
AACE introduces diabetes algorithm
JACKSONVILLE, Fla. A new algorithm designed to help Type 2 diabetes patients achieve glycemic control has appeared online in the September/October edition of the journal Endocrine Practice.
The algorithm, released as a consensus statement by the American Association of Clinical Endocrinologists and the American College of Endocrinology is a one-page resource designed to assist primary care doctors, endocrinologists and others in the management of Type 2 diabetes.
“Depending on a patient’s current A1C level, a physician will use the algorithm to determine whether a mono-, dual- or triple-combination therapy should be considered,” former AACE president and co-chairwoman of the Algorithm Task Force Helena Rodbard said in a statement. “To minimize the risk of diabetic complications, the algorithm will help achieve a hemoglobin A1C value of 6.5 or less when appropriate.”
The task force said it was the first such algorithm that considers currently approved classes of medications emphasizing safety and efficacy while also considering factors such as the overall cost of care.